Document is current

Article History

Received: 17 July 2020

Revised: 24 March 2021

Accepted: 27 October 2021

First Online: 7 December 2021

Declarations

:

: This study was approved by the institutional review board of the Academic Medical Center (AMC) (reference number NL 30802.018.09) and a UK Research Ethics Committee (REC) (reference number 13/LO/0584 Stanmore, London).

: JA has received financial support to attend scientific conferences from MSD, Janssen UK and Gilead Sciences. HZ has served on scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (outside submitted work). JU has received honoraria for preparation of educational materials and has served on an advisory board for Gilead Sciences. MG has received research grants from Gilead Sciences and Janssen-Cilag and honoraria as speaker and/or scientific advisor from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen-Cilag and MSD. PR through his institution has received independent scientific grant support from Gilead Sciences, Janssen Pharmaceuticals Inc., Merck & Co and ViiV Healthcare, and has served on scientific advisory boards for Gilead Sciences, ViiV Healthcare, Merck & Co. and Teva pharmaceutical industries, for which honoraria were all paid to his institution. AW has received honoraria or research grants on behalf of Imperial College London or been a consultant or investigator in clinical trials sponsored by Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Roche and ViiV Healthcare. CAS has received funding for the membership of Data Safety and Monitoring Boards, Advisory Boards and for preparation of educational materials from Gilead Sciences and ViiV Healthcare. For the remaining authors, none were declared.